Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naloxone-Only Clear all
Completed Phase 2 Interventional

Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)

NCT00000451
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence
Interventions
sertraline, naltrexone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

NCT07459166
View directory record Official record
Conditions
Fentanyl Overdose, Fentanyl Poisoning
Interventions
Naloxone Hydrochloride, Fentanyl, Sterile Saline, CS-1103
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 26, 2026, 1:12 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Opioid-related Changes in Neural Activity

NCT02818036
View directory record Official record
Conditions
Social Acceptance
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Tristen Inagaki
Other
Eligibility
18 Years to 35 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults

NCT06216132
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
BIOPIN-6 Active Implant with Naltrexone, BIOPIN-6 Placebo Implant
Combination Product · Device
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine for Prisoners

NCT00574067
View directory record Official record
Conditions
Heroin Addiction
Interventions
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Jessup, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 4 Interventional Results available

Alcohol Disorder hOsPital Treatment Trial

NCT02478489
View directory record Official record
Conditions
Heavy Drinking, Alcohol Dependence, Alcohol Use Disorder
Interventions
Oral naltrexone (PO-NTX), Extended-release injectable naltrexone (XR-NTX)
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 26, 2026, 1:12 PM EDT
Active, not recruiting Not applicable Interventional

Community-based Education, Navigation, and Support Intervention for Military Veterans

NCT05343169
View directory record Official record
Conditions
Overdose, Opioid Use Disorder, HIV Infections
Interventions
Overdose Education and Naloxone Distribution, Advanced Education in Safer Substance Use, Treatment, and Self-Care, Social Service and Health Navigation, Peer Social Support
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Medication-Assisted Treatment for Youth With Substance Use Disorders

NCT02593474
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years to 25 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 4 Interventional

Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults

NCT04219540
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
XR-B (SUBLOCADETM), XR-NTX
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
New Haven, Connecticut • Baltimore, Maryland • Hanover, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reducing Overdose and Substance Use-related Stigma by Training Non-substance-using Friends and Family Members of People Who Use Opioids to Be Harm Reduction Champions

NCT06823453
View directory record Official record
Conditions
Opioid Overdose Prevention, People Who Use Opioids/People With Opioid Use Disorder (OUD), Reduction of Substance Use-related Stigma, Non-substance-using People With a Friend or Family Member Who Uses Opioids, Peer Harm Reduction Support Champions
Interventions
Peer Harm Reduction Support Champion Intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 26, 2026, 1:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Reducing Opioid Mortality in Illinois

NCT04925427
View directory record Official record
Conditions
Opioid Use, Opioid-use Disorder
Interventions
Case Management and Peer Recovery, Naloxone-Only
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Murphysboro, Illinois • Ottawa, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

NCT07179614
View directory record Official record
Conditions
Overdose Risk, Opioid Use Disorder, Stimulant Use Disorders
Interventions
Overdose Prevention Intervention Package (OPIP)
Behavioral
Lead sponsor
Michele Staton
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Barbourville, Kentucky • Harlan, Kentucky • Hyden, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Not yet recruiting Phase 2 Interventional

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

NCT06251609
View directory record Official record
Conditions
Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone
Interventions
Naloxone 2 MG, Saline 2ml
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 1 Interventional

Improved Strategies for Outpatient Opioid Detoxification

NCT01377610
View directory record Official record
Conditions
Opioid Dependence
Interventions
oral naltrexone, Buprenorphine, Vivitrol
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence

NCT01214083
View directory record Official record
Conditions
Alcoholism
Interventions
N-acetylcysteine + high-dose naltrexone (150 mg), High-dose naltrexone (150 mg) alone, Low-dose naltrexone (50 mg) alone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
West Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Not applicable Interventional

Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients

NCT02093559
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Overdose
Interventions
Brief counseling Intervention
Behavioral
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 26, 2026, 1:12 PM EDT
Recruiting Phase 4 Interventional

Endogenous Opioid Response to Injections

NCT06666621
View directory record Official record
Conditions
Low Back Pain, Zygapophyseal Joint Arthritis
Interventions
Normal saline infusion, Naloxone infusion
Drug
Lead sponsor
Middle Tennessee Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 26, 2026, 1:12 PM EDT
Active, not recruiting Phase 3 Interventional

Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl

NCT06089707
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naloxone Nasal Spray
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Will Having Alcohol Treatment Improve Functioning?

NCT01245647
View directory record Official record
Conditions
HIV, Alcoholism
Interventions
Naltrexone, 50mg, once per day for 4 months, Sugar pill, 50mg, once per day for 4 months
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 26, 2026, 1:12 PM EDT
Completed Phase 4 Interventional Results available

Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

NCT00006489
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Post-Traumatic Stress Disorder
Interventions
Cognitive-Behavioral Therapy, Naltrexone, Placebo
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 26, 2026, 1:12 PM EDT